挽救性自体移植联合来那度胺维持对比来那度胺/地塞米松治疗复发多发性骨髓瘤:随机GMMG III期试验ReLApsE
该随机、开放标签、III期、多中心试验将首次至第三次复发的多发性骨髓瘤患者随机分配至移植组(n=139,接受3个Rd再诱导周期、大剂量美法仑200 mg/m2、自体干细胞移植及来那度胺10 mg/日维持)或对照组(n=138,持续Rd)。意向性分析显示中位无进展生存期移植组20.7个月 vs 对照组18.8个月(HR 0.87;95%CI 0.65-1.16;p=0.34),中位总生存期移植组未达到 vs 对照组62.7个月(HR 0.81;95%CI 0.52-1.28;p=0.37)。41例(29%)未接受分配的sHDCT/ASCT。
要点
- 移植组与对照组的中位PFS分别为20.7个月与18.8个月,差异无统计学显著(HR 0.87;95%CI 0.65-1.16;p=0.34)。
- 移植组中位OS未达到,对照组为62.7个月,差异无统计学显著(HR 0.81;95%CI 0.52-1.28;p=0.37)。
- 从sHDCT开始的多变量界标分析显示接受sHDCT/ASCT者PFS和OS更优(p=0.0087/0.0057)。
核心结论
- 将sHDCT/ASCT纳入以Rd为基础的复发治疗在71%患者中可行,意向性分析未显著延长PFS和OS,而接受sHDCT/ASCT的患者可能获益。
研究设计与样本
- 随机、开放标签、III期、多中心试验,纳入首次至第三次复发的多发性骨髓瘤患者。
- 移植组n=139:接受3个Rd再诱导周期(来那度胺25 mg,第1-21天;地塞米松40 mg,第1、8、15、22天;4周为一周期),随后大剂量美法仑200 mg/m2、自体干细胞移植及来那度胺维持10 mg/日。
- 对照组n=138:接受持续Rd治疗。
主要发现
- 中位PFS:移植组20.7个月 vs 对照组18.8个月(HR 0.87;95%CI 0.65-1.16;p=0.34)。
- 中位OS:移植组未达到 vs 对照组62.7个月(HR 0.81;95%CI 0.52-1.28;p=0.37)。
- 41例患者(29%)未接受分配的sHDCT/ASCT,主要原因为早期疾病进展、不良事件和撤回知情同意。
- 从sHDCT开始的多变量界标分析显示,接受sHDCT/ASCT的患者PFS和OS更优(p=0.0087/0.0057)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 41例患者(29%)未接受分配的sHDCT/ASCT,主要原因为早期疾病进展、不良事件和撤回知情同意。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted.
引用
- Goldschmidt H, Baertsch MA, Schlenzka J, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2020. PMID: 32694619. doi:10.1038/s41375-020-0948-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。